fosfomycin and Pain

Fourteen patients with purulent skin diseases were treated orally with fosfomycin (FOM) 1.5-3 g in the tablet form for 1 week to determine its efficacy and safety. The results obtained are summarized as follows. 1. The clinical efficacy rate was 71.4%. A bacteriological eradication rate of 71.4% was obtained. 2. As adverse reactions 3 patients experienced diarrhea and abdominal pain. But in all of these patients, symptoms were relieved with a reduction in dosage. 3. Taking the efficacy and the safety into account, utility rate was assessed to be 71.4%. From these results it is considered that FOM tablets are useful equally to conventional FOM capsules.

Topics: Adolescent; Adult; Aged; Bacteria; Bacterial Infections; Capsules; Diarrhea; Drug Evaluation; Female; Fosfomycin; Humans; Male; Middle Aged; Pain; Skin Diseases, Infectious; Tablets